Fermion Oy Fermion Oy

X
[{"orgOrder":0,"company":"Nimbus Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Nimbus Therapeutics Announces Expansion of its Drug Discovery Pipeline Across Oncology, Immunology and Metabolism","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Discovery","country":"U.S.A","productType":"Small molecule","productStatus":"Undisclosed","date":"June 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"Nimbus Therapeutics"},{"orgOrder":0,"company":"Ginkgo Bioworks","sponsor":"Novo Nordisk","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Ginkgo Bioworks and Novo Nordisk to Collaborate on Expression Systems for Pharmaceutical Products","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Discovery","country":"U.S.A","productType":"Undisclosed","productStatus":"Undisclosed","date":"June 2022","url1":"","url2":"","graph1":"Undisclosed","graph2":"Ginkgo Bioworks"},{"orgOrder":0,"company":"Arbor Biotechnologies, Inc","sponsor":"Vertex Pharmaceuticals","pharmaFlowCategory":"D","amount":"$1,200.0 million","upfrontCash":"Undisclosed","newsHeadline":"Arbor Biotechnologies Announces Expanded Strategic Partnership with Vertex, Now Extending to Precision Gene Editing Using Reverse Transcriptase","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Discovery","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2023","url1":"","url2":"","graph1":"Cell and Gene therapy","graph2":"Arbor Biotechnologies, Inc"},{"orgOrder":0,"company":"Sentia Medical Science","sponsor":"Neurocrine Biosciences","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Sentia Medical Sciences and Neurocrine Biosciences Extend Research Collaboration to Discover Novel CRF Peptides","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Discovery","country":"U.S.A","productType":"Peptide","productStatus":"New Molecular Entity","date":"February 2023","url1":"","url2":"","graph1":"Peptide","graph2":"Sentia Medical Science"},{"orgOrder":0,"company":"Sigilon Therapeutics","sponsor":"Eli Lilly","pharmaFlowCategory":"D","amount":"$344.2 million","upfrontCash":"$344.2 million","newsHeadline":"Lilly to Acquire Sigilon Therapeutics","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Discovery","country":"U.S.A","productType":"Peptide","productStatus":"New Molecular Entity","date":"June 2023","url1":"","url2":"","graph1":"Peptide","graph2":"Sigilon Therapeutics"},{"orgOrder":0,"company":"NexImmune","sponsor":"JDRF","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"NexImmune, Yale, and JDRF Extend Research Partnership for Type 1 Diabetes","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Discovery","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2023","url1":"","url2":"","graph1":"Cell and Gene therapy","graph2":"NexImmune"},{"orgOrder":0,"company":"Fujifilm Cellular Dynamics","sponsor":"Century Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Century Therapeutics and FUJIFILM Cellular Dynamics Announce Licenses for the Development and Commercialization of iPSC-Derived Cell Therapies in Autoimmune and Inflammatory Diseases","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Discovery","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"November 2023","url1":"","url2":"","graph1":"Cell and Gene therapy","graph2":"Fujifilm Cellular Dynamics"},{"orgOrder":0,"company":"Confo Therapeutics","sponsor":"Flanders Innovation & Entrepreneurship","pharmaFlowCategory":"D","amount":"$1.7 million","upfrontCash":"Undisclosed","newsHeadline":"Confo Therapeutics Secures VLAIO Grant Supporting Drug Discovery & Development in Endocrine and Metabolic Diseases","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Discovery","country":"BELGIUM","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2024","url1":"","url2":"","graph1":"Small molecule","graph2":"Confo Therapeutics"},{"orgOrder":0,"company":"Ginkgo Bioworks","sponsor":"Novo Nordisk","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Ginkgo Bioworks and Novo Nordisk Expand Alliance to Collaborate Across R&D Value Chain","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Discovery","country":"U.S.A","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"April 2024","url1":"","url2":"","graph1":"Undisclosed","graph2":"Ginkgo Bioworks"},{"orgOrder":0,"company":"Sentia Medical Science","sponsor":"Neurocrine Biosciences","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Sentia Medical Sciences and Neurocrine Biosciences Extend Research Collaboration to Discover Novel CRF Peptides","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Discovery","country":"U.S.A","productType":"Peptide","productStatus":"New Molecular Entity","date":"April 2024","url1":"","url2":"","graph1":"Peptide","graph2":"Sentia Medical Science"},{"orgOrder":0,"company":"5 Prime Sciences","sponsor":"Eli Lilly","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"5 Prime Sciences Announces Strategic Collaboration with Lilly in Cardio-Metabolic Diseases","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Discovery","country":"U.S.A","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"May 2024","url1":"","url2":"","graph1":"Undisclosed","graph2":"5 Prime Sciences"}]

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Loading...
Filters Filter
×
FILTER:
filter Company
    filter Sponsor
      filter Country
        filter Product Type
          filter News Type

            Active Filter(s):

            Product Type

            Companies

            Details:

            Under the collaboration, 5 Prime Sciences will deploy its state-of-the-art human genetics, multi-omics and AI technologies to identify and validate potential drug targets in cardio-metabolic diseases, including diabetes, obesity, and related conditions.

            Lead Product(s): Undisclosed

            Therapeutic Area: Endocrinology Product Name: Undisclosed

            Highest Development Status: Discovery Product Type: Undisclosed

            Partner/Sponsor/Collaborator: Eli Lilly

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Collaboration May 09, 2024

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            The collaboration will continue to leverage Sentia’s peptide-based platform and Neurocrine’s drug development expertise in CRF biology to discover novel, long-acting corticotropin-releasing factor receptor antagonist peptide therapeutics to address HPA-driven diseases.

            Lead Product(s): Undisclosed

            Therapeutic Area: Endocrinology Product Name: Undisclosed

            Highest Development Status: Discovery Product Type: Peptide

            Partner/Sponsor/Collaborator: Neurocrine Biosciences

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Collaboration April 16, 2024

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            The partnership aims to improve the manufacturing of Novo's medicines for serious chronic diseases, including diabetes and obesity medications by leveraging Ginkgo's synthetic biology platform from discovery through new ways of manufacturing.

            Lead Product(s): Undisclosed

            Therapeutic Area: Endocrinology Product Name: Undisclosed

            Highest Development Status: Discovery Product Type: Undisclosed

            Partner/Sponsor/Collaborator: Novo Nordisk

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Expanded Collaboration April 10, 2024

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            The net proceeds will be used to expand Confo’s ongoing R&D efforts in the discovery of next-generation medicines targeting Class B GPCRs using its patent-protected technology platform.

            Lead Product(s): Undisclosed

            Therapeutic Area: Endocrinology Product Name: Undisclosed

            Highest Development Status: Discovery Product Type: Small molecule

            Partner/Sponsor/Collaborator: Flanders Innovation & Entrepreneurship

            Deal Size: $1.7 million Upfront Cash: Undisclosed

            Deal Type: Funding March 28, 2024

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            The agreement aims for the development and commercialization of cell therapies derived from iPSCs for the treatment of autoimmune and inflammatory diseases, including type 1 diabetes, multiple sclerosis, lupus, and rheumatoid arthritis.

            Lead Product(s): iPSC-derived Cell Therpay

            Therapeutic Area: Endocrinology Product Name: Undisclosed

            Highest Development Status: Discovery Product Type: Cell and Gene therapy

            Partner/Sponsor/Collaborator: Century Therapeutics

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Licensing Agreement November 09, 2023

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            The partnership aims to explore the use of NexImmune’s AIM nanoparticles in combination with an anti-CD3 mAb,a murine surrogate of teplizumab, to tolerize, deplete or modulate diabetes antigen-specific T cells.

            Lead Product(s): Undisclosed

            Therapeutic Area: Endocrinology Product Name: Undisclosed

            Highest Development Status: Discovery Product Type: Cell and Gene therapy

            Partner/Sponsor/Collaborator: JDRF

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Partnership October 24, 2023

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            Through the acquisition, Lilly will gain control of the partnered encapsulated cell therapies, including SIG-002 (human insulin), for the treatment of type 1 diabetes.

            Lead Product(s): Insulin Lispro

            Therapeutic Area: Endocrinology Product Name: SIG-002

            Highest Development Status: Discovery Product Type: Peptide

            Partner/Sponsor/Collaborator: Eli Lilly

            Deal Size: $344.2 million Upfront Cash: $344.2 million

            Deal Type: Acquisition June 29, 2023

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            Under the research collaboration, Sentia’s proprietary peptide-based platform will be used to discover novel compounds as corticotropin-releasing factor receptor antagonist for the treatment of hypothalamic-pituitary-adrenal axis modulated diseases.

            Lead Product(s): Undisclosed

            Therapeutic Area: Endocrinology Product Name: Undisclosed

            Highest Development Status: Discovery Product Type: Peptide

            Partner/Sponsor/Collaborator: Neurocrine Biosciences

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Expanded Collaboration February 14, 2023

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            Under the terms of the agreement, Vertex Pharmaceuticals incorporated will receive rights to Arbor’s novel precision editing technology for up to three diseases.

            Lead Product(s): Undisclosed

            Therapeutic Area: Endocrinology Product Name: Undisclosed

            Highest Development Status: Discovery Product Type: Cell and Gene therapy

            Partner/Sponsor/Collaborator: Vertex Pharmaceuticals

            Deal Size: $1,200.0 million Upfront Cash: Undisclosed

            Deal Type: Expanded Collaboration January 11, 2023

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            Using synthetic biology, Ginkgo and Novo Nordisk will collaborate to unlock the potential of expression systems, which may accelerate and enhance the discovery and development of Novo Nordisk's biological medicines.

            Lead Product(s): Undisclosed

            Therapeutic Area: Endocrinology Product Name: Undisclosed

            Highest Development Status: Discovery Product Type: Undisclosed

            Partner/Sponsor/Collaborator: Novo Nordisk

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Collaboration June 07, 2022

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity
            Post Enquiry
            POST ENQUIRY